Flu Vaccine Moderate
October 27, 2011 by staff
In ananlysis of 31 studies published in Thursday’s issue of the journal The Lancet Infectious Diseases journal, researchers from the U.S. concluded that since the vaccine is often different from the viruses that circulate every flu season, the average efficiency of only 59 percent in healthy young adults.
That estimate was trivalent inactivated vaccine or TIV, the type of vaccine used in Canada.
The effectiveness of influenza vaccine varies from 16 percent to 76 percent, estimated Michael Osterholm, an infectious disease specialist at the University of Minnesota, and colleagues.
There was very little high quality information about how well the vaccine works in children and the elderly – two groups that are at higher risk for influenza-related illness death.
“We need new and better vaccines,” Osterholm said. “We compared the current vaccines level type iPhone 1.0 and what we need is a 10.0″.
In particular, the study authors said, the amount is not enough protection during a pandemic.
“The flu vaccine can provide moderate protection against virologically confirmed influenza, but that protection is very weak or nonexistent in some seasons,” the study authors concluded.
The researchers reviewed studies that tested for the flu virus in lab tests rather than a faster method that seeks an increase in antibodies against influenza, which the researchers tend to overestimate the effectiveness of the vaccine .
The U.S.anlysis could help public health planners to figure out how to get the greatest return on investment, while the vaccine best vaccines have been developed, said Dr. Scott Halperin, director of the Canadian Centre for Vaccinology in Halifax.
“Much of the research that is happening in the field of vaccines against influenza vaccine for the better,” said Halperin. “But having said that, you know 59 or 60 percent is still better than zero percent.”
Vaccine technology is getting better and more effective vaccines may be already in the works, said Halperin.
The study was funded by the Alfred P. Sloan.
Please feel free to send if you have any questions regarding this post , you can contact on
Disclaimer: The views expressed on this site are that of the authors and not necessarily that of U.S.S.POST.